Platelet desialylation is a novel mechanism and a therapeutic target in thrombocytopenia during sepsis: an open-label, multicenter, randomized controlled trial

Abstract

BackgroundStudies in murine models suggested that platelet desialylation was an important mechanism of thrombocytopenia during sepsis.MethodsFirst, we performed a prospective, multicenter, observational study that enrolled septic patients with or without thrombocytopenia to determine the association between platelet desialylation and thrombocytopenia in patients with sepsis, severe sepsis, and septic shock. Gender- and age-matched healthy adults were selected as normal controls in analysis of the platelet desialylation levels (study I). Next, we conducted an open-label randomized controlled trial (RCT) in which the patients who had severe sepsis with thrombocytopenia (platelet counts ≤50 × 109/L) were randomly assigned to receive antimicrobial therapy alone (control group) or antimicrobial therapy plus oseltamivir (oseltamivir group) in a 1:1 ratio (study II). The primary outcomes were platelet desialylation level at study entry, overall platelet response rate within 14 days post-randomization, and all-cause mortality within 28 days post-randomization. Secondary outcomes included platelet recovery time, the occurrence of bleeding events, and the amount of platelets transfused within 14 days post-randomization.ResultsThe platelet desialylation levels increased significantly in the 127 septic patients with thrombocytopenia compared to the 134 patients without thrombocytopenia. A platelet response was achieved in 45 of the 54 patients in the oseltamivir group (83.3%) compared with 34 of the 52 patients in the control group (65.4%; P = 0.045). The median platelet recovery time was 5 days (interquartile range 4–6) in the oseltamivir group compared with 7 days (interquartile range 5–10) in the control group (P = 0.003). The amount of platelets transfused decreased significantly in the oseltamivir group compared to the control group (P = 0.044). There was no difference in the overall 28-day mortality regardless of whether oseltamivir was used. The Sequential Organ Failure Assessment score and platelet recovery time were independent indicators of oseltamivir therapy. The main reason for all of the mortalities was multiple-organ failure.ConclusionsThrombocytopenia was associated with increased platelet desialylation in septic patients. The addition of oseltamivir could significantly increase the platelet response rate, shorten platelet recovery time, and reduce platelet transfusion.Trial registrationChinese Clinical Trial Registry, ChiCTR-IPR-16008542.Electronic supplementary materialThe online version of this article (doi:10.1186/s13045-017-0476-1) contains supplementary material, which is available to authorized users.

Platelets in Sepsis: An Update on Experimental Models and Clinical Data

“…Platelet desialylation is increased in septic patients with thrombocytopenia compared to patients without thrombocytopenia (114). Desialylation occurs during pneumococcal infections, leading to the release of neuraminidase and the exposure of galactose residues, increasing the clearance of platelets by the Ashwell Morrell receptors (AMR) on hepatocytes.…”

Mutation in GNE is associated with severe congenital thrombocytopenia

“…Thrombocytopenia is known to be associated with increased platelet desialylation in septic patients due to altered platelet production/survival. 12 Further, platelet counts were increased in a cohort of influenza patients treated with the sialidase inhibitor oseltamivir (Tamiflu). 13 A platelet clearance system has been shown to exist for desialylated platelets containing macrophages and hepatocytes.…”

Pregnancy in GNE myopathy patients: a nationwide repository survey in Japan

“…Some case reports have indicated a relationship between thrombocytopenia and GNE myopathy [26] or GNE pathogenic variants [27]. Platelet desialylation level is reportedly associated with thrombocytopenia in septic patients [28]. Based on these findings, we analyzed responses regarding thrombocytopenia and low platelet counts from Age Maternal age at pregnancy, M Months after delivery to disease onset, P Parity, NA data not available, B Breast feeding, F Formula feeding, M Mixed feeding 12 participants who had threatened abortion.…”